Local Gene Silencing of Monocyte Chemoattractant Protein-1 Prevents Vulnerable Plaque Disruption in Apolipoprotein E-Knockout Mice
Authors:
- Peng Fei ZhangPZPeng Fei Zhang
- Shi Fang DingSDShi Fang Ding
- Yan WangYWYan Wang
- Mei ZhangMZMei Zhang
- Mei NiMNMei Ni
- Yun ZhangYZYun Zhang
Open Access
- 12 March 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (3) , e33497
Abstract
Monocyte chemoattractant protein-1 (MCP-1), a CC chemokine (CCL2), has been demonstrated to play important roles in atherosclerosis and becoming an important therapeutic target for atherosclerosis. The present study was undertaken to test the hypothesis that local RNAi of MCP-1 by site-specific delivery of adenovirus-mediated small hairpin RNA (shRNA) may enhance plaque stability and prevent plaque disruption in ApoE−/− mice. We designed an adenovirus-mediated shRNA against mouse MCP-1 (rAd5-MCP-1-shRNA). Male apolipoprotein E-knockout (ApoE−/−) mice (n = 120) were fed a high-fat diet and vulnerable plaques were induced by perivascular placement of constrictive collars around the carotid artery, intraperitoneal injection of lipopolysaccharide and stress stimulation. Mice were randomly divided into RNA interference (Ad-MCP-1i) group receiving local treatment of rAd5-MCP-1-shRNA suspension, Ad-EGFP group receiving treatment of rAd5-mediated negative shRNA and mock group receiving treatment of saline. Two weeks after treatment, plaque disruption rates were significantly lower in the Ad-MCP-1i group than in the Ad-EGFP group (13.3% vs. 60.0%, P = 0.01), and local MCP-1 expression was significantly inhibited in the Ad-MCP-1i group confirmed by immunostaining, qRT-PCR and western blot (P<0.001). Compared with the Ad-EGFP group, carotid plaques in the Ad-MCP-1i group showed increased levels of collagen and smooth muscle cells, and decreased levels of lipid and macrophages. The expression of inflammatory cytokines and activities of matrix metalloproteinases (MMPs) were lower in the Ad-MCP-1i group than in the Ad-EGFP group. In conclusion, site-specific delivery of adenoviral-mediated shRNA targeting mouse MCP-1 downregulated MCP-1 expression, turned a vulnerable plaque into a more stable plaque phenotype and prevented plaque disruption. A marked suppression of the local inflammatory cytokine expression may be the central mechanism involved.Keywords
This publication has 34 references indexed in Scilit:
- CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE−/− miceAtherosclerosis, 2010
- Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implicationsClinical Science, 2009
- Atherosclerotic plaque disruption induced by stress and lipopolysaccharide in apolipoprotein E knockout miceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Dominant‐negative mutation of monocyte chemoattractant protein‐1 prevents vulnerable plaques from rupture in rabbits independent of serum lipid levelsJournal of Cellular and Molecular Medicine, 2008
- Putative Murine Models of Plaque RuptureArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Perivascular gene transfer of NADPH oxidase inhibitor suppresses angioplasty-induced neointimal proliferation of rat carotid arteryAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Challenges for RNAi in vivoTrends in Biotechnology, 2004
- BACE1 Suppression by RNA Interference in Primary Cortical NeuronsJournal of Biological Chemistry, 2004
- Inflammation and AtherosclerosisCirculation, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001